Get started
Author

Yingjia Sun

Observed names: Y. Sun, Y.-m. Sun, Ying-Jia Sun
ORCID: 0000-0001-8234-5931
Observed ORCID: 0000-0001-8234-5931
OpenAlex ID: A5016978561
NF-κB-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10
2015 · Yingjia Sun, Xinghao Ai, et al. · Oncotarget · 79
PDF
A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity
2014 · Xinghao Ai, Yingjia Sun, et al. · Amino Acids · 40
The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients
2022 · Ying Yang, Shengping Shen, et al. · Translational Lung Cancer Research · 19
PDF
Circumferential pulmonary vein isolation: the role of key target sites
2008 · X.-h. Wang, H.-f. Shi, et al. · EP Europace · 18
PDF
Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment
2022 · Yingjia Sun, Ziming Li, et al. · Journal of Clinical Medicine · 16
PDF
Neoadjuvant Chemoimmunotherapy Increases Tumor Immune Lymphocytes Infiltration in Resectable Non-small Cell Lung Cancer
2023 · Tianxiang Chen, Zhengqi Cao, et al. · Annals of Surgical Oncology · 15
Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report
2021 · Xiaomin Niu, Yingjia Sun, et al. · Frontiers in Oncology · 12
PDF
Integrated discovery of FOXO1–DNA stabilizers from marine natural products to restore chemosensitivity to anti-EGFR-based therapy for metastatic lung cancer
2016 · Yingjia Sun, Xinghao Ai, et al. · Molecular BioSystems · 12
No significant association between the XRCC3 Thr241Met polymorphism and lung cancer risk: a meta-analysis
2013 · Yun-Hua Xu, Lin-Ping Gu, et al. · Tumor Biology · 12
Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors
2023 · R. Wang, V. Baxi, et al. · ESMO Open · 8
PDF
Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
2023 · Xingyuan Li, Huayan Huang, et al. · Frontiers in Oncology · 6
PDF
Tagrisso incremental therapy in a case of meningeal metastasis of lung cancer with EGFR mutation: a case report
2022 · Yingjia Sun, Xinghao Ai, et al. · Translational Lung Cancer Research · 6
PDF
New-Onset Arrhythmias in Advanced Lung Cancer Patients Undergoing Anlotinib Treatment
2025 · Conghui Shang, Hao Wang, et al. · Cardiovascular Toxicology · 1
PDF
Clinical outcomes of SMARCA4-deficient thoracic tumor patients and therapeutic value of immune checkpoint inhibitors in advanced stage patients
2026 · Qing Jiang, Shuya Mu, et al. · BMC Cancer
FGFR1 copy number gain is independently associated with shorter progression-free survival in advanced lung squamous cell carcinoma treated with first-line immune checkpoint inhibitor-based therapy
2026 · Shuya Mu, Xingyuan Li, et al. · Frontiers in Immunology
PDF
ASO Video Abstract: Neoadjuvant Chemo-Immunotherapy Increases Tumor Immune Lymphocytes Infiltration in Resectable NSCLC
2023 · Tianxiang Chen, Zhengqi Cao, et al. · Annals of Surgical Oncology
PDF
ASO Author Reflections: Immune Microenvironment Indicators in Neoadjuvant Chemo-Immunotherapy
2023 · Tianxiang Chen, Zhengqi Cao, et al. · Annals of Surgical Oncology
Works count: 17
Citation count: 243
H-index: 9
I10-index: 9
Year
Topic
Type